Mercy Neufeld
Research Subjects
Mercy Neufeld has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ada Ezeogu
PrimeLife360 Wellness, 20 Wenlock Road, London N1 7GU, UK
2 shared publications - Adamu Onu
Institute of Medical Sciences Africa, Abuja 900108, Nigeria
2 shared publications - Charles Omale
Royal Eye Hospital & Medical Centre, Abuja 900108, Nigeria
2 shared publications - Dung-Gwom Pam Stephen
Department of Internal Medicine, Jos University Teaching Hospital, Jos 930232, Nigeria
2 shared publications - Edward Irobi
College of Health Sciences and Public Policy, Walden University, 100 Washington Avenue South—Suite 1210, Minneapolis, MN 55401, USA
2 shared publications - Emmanuel Davies
PrimeLife360 Wellness, 20 Wenlock Road, London N1 7GU, UK
2 shared publications
Latest Publications
- Open Access
- 28 September 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (4) , 62
Keystone Species Restoration: Therapeutic Effects of Bifidobacterium infantis and Lactobacillus reuteri on Metabolic Regulation and Gut–Brain Axis Signaling—A Qualitative Systematic Review (QualSR)
Background: The human gut microbiome—a diverse ecosystem of trillions of microorganisms—plays an essential role in metabolic, immune, and neurological regulation. However, modern lifestyle factors such as antibiotic overuse, cesarean delivery, reduced breastfeeding, processed and high-sodium diets, alcohol intake, smoking, and exposure to environmental toxins (e.g., glyphosate) significantly reduce microbial diversity. Loss of keystone species like Bifidobacterium infantis (B. infantis) and Lactobacillus reuteri (L. reuteri) contributes to gut dysbiosis, which has been implicated in chronic metabolic, autoimmune, cardiovascular, and neurodegenerative conditions. Materials and Methods: This Qualitative Systematic Review (QualSR) synthesized data from over 547 studies involving human participants and standardized microbiome analysis techniques, including 16S rRNA sequencing and metagenomics. Studies were reviewed for microbial composition, immune and metabolic biomarkers, and clinical outcomes related to microbiome restoration strategies. Results: Multiple cohort studies have consistently reported a 40–60% reduction in microbial diversity among Western populations compared to traditional societies, particularly affecting short-chain fatty acid (SCFA)-producing bacteria. Supplementation with B. infantis is associated with a significant reduction in systemic inflammation—including a 50% decrease in C-reactive protein (CRP) and reduced tumor necrosis factor-alpha (TNF-α) levels—alongside increases in regulatory T cells and anti-inflammatory cytokines interleukin-10 (IL-10) and transforming growth factor-beta 1 (TGF-β1). L. reuteri demonstrates immunomodulatory and neurobehavioral benefits in preclinical models, while both probiotics enhance epithelial barrier integrity in a strain- and context-specific manner. In murine colitis, B. infantis increases ZO-1 expression by ~35%, and L. reuteri improves occludin and claudin-1 localization, suggesting that keystone restoration strengthens barrier function through tight-junction modulation. Conclusions: Together, these findings support keystone species restoration with B. infantis and L. reuteri as a promising adjunctive strategy to reduce systemic inflammation, reinforce gut barrier integrity, and modulate gut–brain axis (GBA) signaling, indicating translational potential in metabolic and neuroimmune disorders. Future research should emphasize personalized microbiome profiling, long-term outcomes, and transgenerational effects of early-life microbial disruption.
- 28 September 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (4) , 62
Open AccessKeystone Species Restoration: Therapeutic Effects of Bifidobacterium infantis and Lactobacillus reuteri on Metabolic Regulation and Gut–Brain Axis Signaling—A Qualitative Systematic Review (QualSR)
Background: The human gut microbiome—a diverse ecosystem of trillions of microorganisms—plays an essential role in metabolic, immune, and neurological regulation. However, modern lifestyle factors such as antibiotic overuse, cesarean delivery, reduced breastfeeding, processed and high-sodium diets, alcohol intake, smoking, and exposure to environmental toxins (e.g., glyphosate) significantly reduce microbial diversity. Loss of keystone species like Bifidobacterium infantis (B. infantis) and Lactobacillus reuteri (L. reuteri) contributes to gut dysbiosis, which has been implicated in chronic metabolic, autoimmune, cardiovascular, and neurodegenerative conditions. Materials and Methods: This Qualitative Systematic Review (QualSR) synthesized data from over 547 studies involving human participants and standardized microbiome analysis techniques, including 16S rRNA sequencing and metagenomics. Studies were reviewed for microbial composition, immune and metabolic biomarkers, and clinical outcomes related to microbiome restoration strategies. Results: Multiple cohort studies have consistently reported a 40–60% reduction in microbial diversity among Western populations compared to traditional societies, particularly affecting short-chain fatty acid (SCFA)-producing bacteria. Supplementation with B. infantis is associated with a significant reduction in systemic inflammation—including a 50% decrease in C-reactive protein (CRP) and reduced tumor necrosis factor-alpha (TNF-α) levels—alongside increases in regulatory T cells and anti-inflammatory cytokines interleukin-10 (IL-10) and transforming growth factor-beta 1 (TGF-β1). L. reuteri demonstrates immunomodulatory and neurobehavioral benefits in preclinical models, while both probiotics enhance epithelial barrier integrity in a strain- and context-specific manner. In murine colitis, B. infantis increases ZO-1 expression by ~35%, and L. reuteri improves occludin and claudin-1 localization, suggesting that keystone restoration strengthens barrier function through tight-junction modulation. Conclusions: Together, these findings support keystone species restoration with B. infantis and L. reuteri as a promising adjunctive strategy to reduce systemic inflammation, reinforce gut barrier integrity, and modulate gut–brain axis (GBA) signaling, indicating translational potential in metabolic and neuroimmune disorders. Future research should emphasize personalized microbiome profiling, long-term outcomes, and transgenerational effects of early-life microbial disruption.
- Open Access
- 13 August 2025
- Published by MDPI AG in Preprints.org
Keystone Species Restoration: Therapeutic Effects of Bifidobacterium infantis and Lactobacillus reuteri on Metabolic Regulation and Gut-Brain Axis Signaling—A Qualitative Systematic Review (QualSR)
Background: The human gut microbiome—a diverse ecosystem of trillions of microorganisms—plays a critical role in metabolic, immune, and neurological regulation. However, modern lifestyle factors such as antibiotic overuse, cesarean delivery, reduced breastfeeding, processed and high-sodium diets, alcohol intake, smoking, and exposure to environmental toxins (e.g., glyphosate) have significantly reduced microbial diversity. Loss of keystone species like Bifidobacterium infantis and Lactobacillus reuteri contributes to gut dysbiosis, which has been implicated in chronic metabolic, autoimmune, cardiovascular, and neurodegenerative conditions. Materials & Methods: This Qualitative Systematic Review (QualSR) synthesized data from over 547 studies involving human participants and standardized microbiome analysis techniques, including 16S rRNA sequencing and metagenomics. Studies were reviewed for microbial composition, immune and metabolic biomarkers, and clinical outcomes related to microbiome restoration strategies. Results: Findings reveal a 40–60% reduction in microbial diversity among Western populations compared to traditional societies, particularly affecting SCFA-producing bacteria. Supplementation with B. infantis was associated with a significant reduction in systemic inflammation—including a 50% decrease in C-reactive protein (CRP) and reduced TNF-α levels—alongside increases in regulatory T cells and anti-inflammatory cytokines (IL-10, TGF-β1). L. reuteri demonstrated additional immunomodulatory effects and neurobehavioral benefits in preclinical models. Restoration interventions led to a 30–45% increase in tight junction protein expression and a 25–50% reduction in overall inflammation, suggesting improved gut barrier function and systemic immune balance. Conclusion: Restoring gut microbiota diversity through keystone species like B. infantis and L. reuteri holds therapeutic potential for a wide range of chronic inflammatory, metabolic, and neuroimmune disorders. Strengthening gut barrier integrity and reducing systemic inflammation by up to 50% underscores the microbiome’s relevance in immunometabolic health. Future research should emphasize personalized microbiome profiling, long-term outcomes, and transgenerational effects of early-life microbial disruption.
- 13 August 2025
- Published by MDPI AG in Preprints.org
Open AccessKeystone Species Restoration: Therapeutic Effects of Bifidobacterium infantis and Lactobacillus reuteri on Metabolic Regulation and Gut-Brain Axis Signaling—A Qualitative Systematic Review (QualSR)
Background: The human gut microbiome—a diverse ecosystem of trillions of microorganisms—plays a critical role in metabolic, immune, and neurological regulation. However, modern lifestyle factors such as antibiotic overuse, cesarean delivery, reduced breastfeeding, processed and high-sodium diets, alcohol intake, smoking, and exposure to environmental toxins (e.g., glyphosate) have significantly reduced microbial diversity. Loss of keystone species like Bifidobacterium infantis and Lactobacillus reuteri contributes to gut dysbiosis, which has been implicated in chronic metabolic, autoimmune, cardiovascular, and neurodegenerative conditions. Materials & Methods: This Qualitative Systematic Review (QualSR) synthesized data from over 547 studies involving human participants and standardized microbiome analysis techniques, including 16S rRNA sequencing and metagenomics. Studies were reviewed for microbial composition, immune and metabolic biomarkers, and clinical outcomes related to microbiome restoration strategies. Results: Findings reveal a 40–60% reduction in microbial diversity among Western populations compared to traditional societies, particularly affecting SCFA-producing bacteria. Supplementation with B. infantis was associated with a significant reduction in systemic inflammation—including a 50% decrease in C-reactive protein (CRP) and reduced TNF-α levels—alongside increases in regulatory T cells and anti-inflammatory cytokines (IL-10, TGF-β1). L. reuteri demonstrated additional immunomodulatory effects and neurobehavioral benefits in preclinical models. Restoration interventions led to a 30–45% increase in tight junction protein expression and a 25–50% reduction in overall inflammation, suggesting improved gut barrier function and systemic immune balance. Conclusion: Restoring gut microbiota diversity through keystone species like B. infantis and L. reuteri holds therapeutic potential for a wide range of chronic inflammatory, metabolic, and neuroimmune disorders. Strengthening gut barrier integrity and reducing systemic inflammation by up to 50% underscores the microbiome’s relevance in immunometabolic health. Future research should emphasize personalized microbiome profiling, long-term outcomes, and transgenerational effects of early-life microbial disruption.